Target Name: MIR23A
NCBI ID: G407010
Review Report on MIR23A Target / Biomarker Content of Review Report on MIR23A Target / Biomarker
MIR23A
Other Name(s): MIRN23A | hsa-miR-23a-5p | hsa-mir-23a | hsa-miR-23a-3p | miRNA23A | mir-23a | MicroRNA 23a | microRNA 23a

MIR23A: A Potential Drug Target and Biomarker

MIR23A, also known as MIRN23A, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and a potential drug development candidate.

MIR23A is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. It is expressed in a variety of tissues and cells and is involved in the regulation of gene expression, cell growth, and differentiation.

One of the defining features of MIR23A is its unique structure. It is a 20-nt RNA molecule that consists of a single exon. Despite its small size, MIR23A has a highly conserved core structure that is similar to other miRNAs. It has a predicted localization to the nuclear kernel, a structure found in the cytoplasm of eukaryotic cells that is involved in the regulation of gene expression.

MIR23A's function is still being fully understood, but research has shown that it plays a role in the regulation of cellular processes such as cell growth, apoptosis, and apoptosis. It has also been shown to be involved in the inflammation regulation of various cellular pathways, including the cell cycle, cell signaling, and inflammation.

One of the most promising aspects of MIR23A is its potential as a drug target. Its unique structure and function make it an attractive target for small molecules that can modulate its activity. Researchers have identified several potential drug candidates that have been shown to interact with MIR23A and have the potential to be developed into drugs for various diseases.

One of the most promising candidates is a small molecule called TK-985, which is a potent inhibitor of MIR23A. TK-985 has been shown to inhibit the activity of MIR23A and has been shown to be effective in preclinical studies in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another potential drug candidate is a small molecule called U-8712, which is a MIR23A inhibitor that has been shown to be effective in preclinical studies in treating various diseases, including cancer and neurodegenerative diseases.

In addition to its potential as a drug target, MIR23A is also a potential biomarker. Its unique structure and function make it an attractive target for diagnostic tools that can detect and monitor its levels in various tissues and cells. Researchers have shown that MIR23A is expressed in a variety of tissues and cells, including brain, heart, and cancer cells, and has been used as a biomarker in a variety of diseases, including cancer and neurodegenerative diseases.

One of the most promising applications of MIR23A as a biomarker is its potential to monitor the effectiveness of anti-cancer drugs. Cancer cells often have increased levels of MIR23A, making them more resistant to traditional cancer treatments. By monitoring the levels of MIR23A in cancer cells before and after treatment, researchers can assess the effectiveness of anti-cancer drugs and identify potential areas for improvement.

In conclusion, MIR23A is a non-coding RNA molecule that has the potential to be a drug target and biomarker for various diseases. Its unique structure and function make it an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand its role in the regulation of cellular processes and to identify potential drug candidates.

Protein Name: MicroRNA 23a

The "MIR23A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR23A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A